Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study
Authors:
Open Access
- 6 January 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e043736
Abstract
Background: Bio‐ADM (bioactive adrenomedullin) is a vasoactive peptide hormone that predicts clinical outcomes in heart failure—the main driver of adverse outcomes in cardiac amyloidosis (CA). This prospective observational study sought to assess the prognostic role of bio‐ADM in CA. Methods: Patients with CA were enrolled from amyloid centers in Germany (observation cohort), Japan, and the United States (combined validation cohort). Bio‐ADM was quantified using the sphingotest bio‐ADM assay. Associations of bio‐ADM with all‐cause death and major adverse cardiovascular events over 2 years were assessed using Kaplan–Meier and Cox regression analyses. Likelihood ratio chi‐square tests for nested models evaluated whether adding bio‐ADM improves validated prognostic staging systems. Results: In both the German observation cohort (n=86) and the combined validation cohort from Japan and the United States (n=124), elevated bio‐ADM (>29 pg/mL) was associated with more frequent all‐cause death and major adverse cardiovascular events. Bio‐ADM remained independently associated with impaired overall ( P P 29 pg/mL) significantly improved the prognostic accuracy of the National Amyloidosis Centre (C‐index 0.674 to 0.787; P =0.002) and MayoATTR (C‐index 0.662 to 0.757; P <0.001) staging systems for cardiac transthyretin amyloidosis. Adding bio‐ADM to staging systems for cardiac immunoglobulin light chain amyloidosis yielded no significant changes. Conclusions: Bio‐ADM is a promising prognostic biomarker, especially in cardiac transthyretin amyloidosis, where it improved risk stratification when added to established staging systems. Further research is needed to clarify its role as part of staging systems for cardiac immunoglobulin light chain amyloidosis.Keywords
This publication has 69 references indexed in Scilit:
- Myocardial Perfusion in Cardiac AmyloidosisEuropean Journal of Heart Failure, 2024
- Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of CardiologyEuropean Journal of Heart Failure, 2022
- Bioactive Adrenomedullin for Assessment of Venous Congestion in Heart FailureESC Heart Failure, 2022
- Use of biomarkers to diagnose and manage cardiac amyloidosisEuropean Journal of Heart Failure, 2021
- Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failureEuropean Journal of Heart Failure, 2020
- Clinical Value of Pre-Discharge Bio-Adrenomedullin as a Marker of Residual Congestion and High Risk of Heart Failure Hospital ReadmissionEuropean Journal of Heart Failure, 2019
- Bio-Adrenomedullin as a Marker of Congestion in Patients with New-Onset and Worsening Heart FailureEuropean Journal of Heart Failure, 2019
- Adrenomedullin in Heart Failure: Pathophysiology and Therapeutic ApplicationEuropean Journal of Heart Failure, 2018
- Bio-Adrenomedullin as a Potential Quick, Reliable, and Objective Marker of Congestion in Heart FailureEuropean Journal of Heart Failure, 2018
- Intramyocardial Inflammation Predicts Adverse Outcome in Patients with Cardiac AL AmyloidosisEuropean Journal of Heart Failure, 2017